Next Generation Diabetes Therapy and Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Next Generation Diabetes Therapy and Drug Delivery Market was valued at USD 22.25 Billion in 2024, and is expected to reach USD 33.49 Billion by 2030, rising at a CAGR of 7.25%. Diabetes is a chronic disease that affects millions of people worldwide, and its management requires ongoing efforts to control blood sugar levels and prevent complications. The field of diabetes therapy and drug delivery has seen remarkable progress in recent years, thanks to innovative research and technology. The global next-generation diabetes therapy and drug delivery market is on the cusp of transformative change, offering new hope for individuals living with diabetes.

Diabetes is a metabolic disorder characterized by elevated blood sugar levels, resulting from the body's inability to produce enough insulin or effectively utilize the insulin it produces. It can lead to serious complications such as heart disease, kidney problems, vision loss, and neuropathy if not properly managed. Effective diabetes therapy and drug delivery are essential to help patients lead healthier lives. The global market for next-generation diabetes therapy and drug delivery is undergoing rapid expansion.

Several factors contribute to this growth, including a rising global incidence of diabetes, technological advancements, and increased awareness about the importance of diabetes management. One of the key drivers of innovation in diabetes therapy and drug delivery is the advancement of technology. Continuous glucose monitoring (CGM) systems, insulin pumps, and smart insulin pens are some examples of cutting-edge technologies that have revolutionized the way patients manage their diabetes. These devices provide real-time data and automate insulin delivery, improving precision and convenience.

Key Market Drivers

Growing Diabetes Epidemic

The global diabetes epidemic is a major public health concern, affecting individuals of all ages and backgrounds. The increasing prevalence of diabetes, as highlighted by the 2021 IDF Diabetes Atlas, is a significant driver for the growth of the global next-generation diabetes therapy and drug delivery market. Currently, 10.5% of adults (ages 20-79) are living with diabetes, with nearly half unaware of their condition. By 2045, projections indicate that 1 in 8 adults, or around 783 million people, will be affected by diabetes, representing a 46% increase. The majority of these cases (over 90%) will be type 2 diabetes, which is influenced by a complex interplay of socio-economic, demographic, environmental, and genetic factors.

As the number of diabetes cases continues to rise, the demand for innovative therapies and advanced drug delivery solutions will accelerate, driving the growth of this market. Diabetes-related medical expenses and lost productivity have a substantial economic cost, both on a global and individual scale. Recognizing the dire need for more effective and patient-friendly treatments, the Next Generation Diabetes Therapy and Drug Delivery market has witnessed significant growth. Innovations in this field aim to address the unique challenges faced by people with diabetes, ultimately leading to better disease management and improved quality of life.

Traditional insulin injections are often inconvenient and painful for individuals with diabetes. The development of advanced insulin delivery systems, such as insulin pumps and continuous glucose monitoring devices, has revolutionized diabetes management. These devices offer precise insulin delivery, reduce the risk of hypoglycemia, and provide real-time glucose monitoring, thus improving overall glycemic control. Researchers have been working on developing an oral insulin delivery method, which would eliminate the need for injections. This technology has the potential to significantly improve patient adherence to treatment regimens. The concept of an artificial pancreas is a game-changer in diabetes therapy.

It combines continuous glucose monitoring with automated insulin delivery, creating a closed-loop system that can respond to fluctuations in blood glucose levels in real-time. Such innovations offer the promise of better blood sugar control and fewer diabetes-related complications. Advances in genomics and personalized medicine have enabled the development of diabetes treatments tailored to an individual's genetic makeup. These treatments may prove to be more effective and have fewer side effects than traditional therapies. Telemedicine and digital health solutions have become integral in diabetes management. They provide remote monitoring and support, allowing healthcare professionals to track patients' progress and adjust treatment plans as necessary.

The global Next Generation Diabetes Therapy and Drug Delivery market is expected to grow significantly in the coming years. Factors such as the increasing prevalence of diabetes, the need for more patient-friendly treatment options, and ongoing research and development in the field of diabetes management contribute to this growth. The market is also likely to witness collaborations between pharmaceutical companies, medical device manufacturers, and digital health companies to offer comprehensive solutions for diabetes care. Furthermore, regulatory bodies around the world are increasingly supportive of innovation in diabetes management, streamlining the approval process for new therapies and devices. This has created a favorable environment for companies seeking to bring new products to the market.

Rising Healthcare Expenditure

The rising healthcare expenditure worldwide, coupled with the growing prevalence of diabetes, has created a strong impetus for the development and adoption of next-generation diabetes therapy and drug delivery solutions. These innovative approaches offer the potential to reduce the economic and human toll of diabetes, improve patient outcomes, and enhance the sustainability of healthcare systems. As research and development in this field continue to progress, the future holds promise for individuals living with diabetes and those dedicated to providing them with the best care possible. In 2023, U.S.

healthcare spending increased by 7.5%, reaching USD 4.9 trillion, or USD 14,570 per person, according to the National Health Expenditure Accounts. This represents 17.6% of the nation's Gross Domestic Product (GDP). The rising healthcare expenditure highlights the urgent need for more effective and sustainable medical solutions, particularly in the management of chronic diseases such as diabetes. This growing financial burden is driving the demand for innovative diabetes therapies and advanced drug delivery systems, fueling expansion in the global next-generation diabetes therapy and drug delivery market.

The growth of the global next generation diabetes therapy and drug delivery market is closely tied to the increasing healthcare expenditure seen in many countries. As the number of people living with diabetes continues to grow, healthcare systems are under increasing pressure to provide effective and cost-efficient solutions. Investing in next-generation therapies and drug delivery systems is seen as a way to address this challenge. Diabetes imposes a significant economic burden on both individuals and healthcare systems. The cost of treating diabetes-related complications, hospitalizations, and medications is substantial.

Innovations in diabetes management can help reduce these costs and improve overall healthcare sustainability. The shift towards patient-centered care and the demand for improved quality of life has led to the development of next-generation therapies that focus on patient convenience, adherence, and outcomes. Advances in medical technology, data analytics, and artificial intelligence are driving the development of innovative solutions in diabetes management. These technologies not only improve patient care but also contribute to healthcare system efficiency.

Key Market Challenges

Regulatory and Approval Processes

One of the primary challenges in the global diabetes therapy market is the stringent regulatory environment. Developing new therapies and drug delivery methods requires extensive testing, clinical trials, and rigorous safety and efficacy assessments. Obtaining regulatory approval can be a long and costly process, often taking years. This can discourage smaller companies with innovative solutions from entering the market, as they may not have the resources to navigate the regulatory hurdles effectively.

Cost of Innovation

Innovation in diabetes therapy and drug delivery comes at a high cost. Developing and testing new technologies, medications, and delivery methods requires substantial investments in research and development. Many innovative therapies and drug delivery systems remain out of reach for patients due to their high price points. This cost can be a significant barrier to access for individuals with diabetes, particularly in low-income and underprivileged regions.

Patient Adherence

Patient adherence to diabetes therapies and drug delivery methods is a persistent challenge. Even with the introduction of innovative options, patients may struggle to follow their treatment regimens. This non-adherence can lead to suboptimal health outcomes and increased healthcare costs. There is a need for greater patient education, support, and user-friendly therapies to enhance adherence.

Integration of Digital Health Solutions

The integration of digital health solutions and technology into diabetes therapy and drug delivery is a promising avenue, but it comes with its own set of challenges. Ensuring data privacy and security while using apps, wearable devices, and telehealth platforms is critical. Additionally, not all patients have access to smartphones or the internet, potentially leaving some individuals with diabetes at a disadvantage.

Tailoring Therapies to Individual Needs

Diabetes is a highly individualized condition. What works for one patient may not work for another. Personalized medicine has the potential to revolutionize diabetes management, but developing tailored therapies and drug delivery methods can be complex and costly. It requires a deep understanding of a patient's genetic, metabolic, and lifestyle factors, which is not always feasible in routine clinical practice.

Global Disparities

Access to next-generation diabetes therapies and drug delivery methods is not evenly distributed around the world. High-income countries often have better access to cutting-edge treatments, while low and middle-income nations may face limited resources and infrastructure. Addressing these global disparities is a significant challenge in ensuring equitable diabetes care.

Competition and Market Saturation

As the global diabetes therapy and drug delivery market becomes more competitive, companies must continually innovate to stay ahead. However, the market may become saturated with similar products, making it difficult for newcomers to gain a foothold. Additionally, competitive pricing can lead to price wars that negatively impact profit margins.

Key Market Trends

Technological Advancements

Diabetes has emerged as a global health crisis, affecting millions of people worldwide. As the prevalence of diabetes continues to rise, so does the demand for innovative and effective treatments. Technological advancements are playing a pivotal role in shaping the next generation of diabetes therapy and drug delivery solutions, driving the growth of the global diabetes market. Continuous Glucose Monitoring (CGM) Systems have revolutionized diabetes management by providing real-time glucose level data. These devices, often paired with smartphone apps, enable patients and healthcare providers to monitor and adjust insulin levels more accurately.

The development of smaller, more comfortable sensors and improved data accuracy has made CGM a game-changer in diabetes therapy. Artificial pancreas systems, also known as closed-loop systems, combine CGM technology with insulin pumps. These devices automatically adjust insulin delivery based on real-time glucose data, reducing the burden on patients and improving blood sugar control. The FDA's approval of such systems has further advanced the adoption of this technology. Traditional insulin pens and pumps have evolved into smart, connected devices that track insulin doses and provide reminders for patients. They allow healthcare providers to remotely monitor and adjust insulin regimens, enhancing patient care and compliance.

In June 2024, Vertex Pharmaceuticals reported that its VX-880 Diabetes Cell Therapy is progressing toward its goal of eliminating severe hypoglycemic events in type 1 diabetes (T1D) patients. The most recent data from the phase 1/2 FORWARD trial, presented at the American Diabetes Association’s 84th Scientific Sessions, further support VX-880’s potential to reduce or eliminate insulin dependence. VX-880 is an allogeneic, stem cell-derived insulin-producing islet cell therapy. Following a single infusion, all 12 patients in the study demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90.

With mild to moderate adverse events primarily related to immunosuppressive treatment, no serious side effects were linked directly to VX-880. This technological breakthrough highlights the transformative potential of advanced therapies in diabetes management and represents a key development in the next-generation diabetes therapy and drug delivery market, driving further innovation in the field. Smartphone apps and digital platforms provide patients with tools for tracking their glucose levels, medications, and dietary habits. These platforms also offer educational resources and connect patients with healthcare professionals, promoting self-management and facilitating more personalized treatment plans.

Technological advancements have also led to the development of innovative drug delivery systems, such as inhalable insulin and smart patches. These solutions aim to improve the ease of insulin administration and reduce the stigma associated with diabetes treatment. The convergence of these technological advancements has resulted in a booming market for next-generation diabetes therapy and drug delivery solutions. The growth is driven by the increasing prevalence of diabetes, rising patient awareness, and the demand for more convenient and efficient treatment options. Moreover, ongoing research and development in the field of diabetes technology are fueling innovation. Pharmaceutical and medical device companies are investing heavily in improving existing technologies and developing new solutions, which further propel the market's expansion.

Segmental Insights

Product Type Insights

Based on Product Type, the CGM Systems emerged as the fastest growing segment in the global market for Next Generation Diabetes Therapy and Drug Delivery during the forecast period. CGM systems offer real-time, continuous monitoring of blood glucose levels, enabling individuals with diabetes to make immediate adjustments to their insulin regimen and lifestyle. This capability to track glucose variations throughout the day enhances diabetes management and improves patient outcomes. In recent years, CGM technology has advanced significantly, becoming more accurate, compact, and user-friendly. New models now integrate seamlessly with smartphones and insulin pumps, simplifying glucose level tracking for users.

The ability to sync with other digital health tools and wearables further enhances the appeal of CGM systems for both patients and healthcare providers. For instance, in July 2024, Roche received the CE Mark for its Accu-Chek SmartGuide CGM solution, which will be available for adults with type 1 and type 2 diabetes on flexible insulin therapy. The system sends real-time glucose readings to the Accu-Chek SmartGuide app every five minutes, and the app uses this data to detect glucose trends and predict future levels.

The growing demand for personalized, data-driven healthcare is also driving the adoption of CGM systems, as they offer in-depth insights into how various factors, including diet, exercise, medications, and stress, influence glucose levels. CGM systems have gained significant clinical support, with numerous studies highlighting their effectiveness in lowering HbA1c levels and reducing hypoglycemic episodes. Additionally, as regulatory bodies such as the FDA continue to approve newer models, the market for CGM systems is expanding rapidly. These advancements position CGM systems as a key driver of growth in the next-generation diabetes therapy and drug delivery market, addressing the increasing need for more efficient and effective diabetes management solutions.

End user Insights

Based on End user, the Home Healthcare emerged as the dominating segment in the global market for Next Generation Diabetes Therapy and Drug Delivery in 2024. There is an increasing shift towards enabling patients to manage their diabetes at home, driven by technological advancements such as CGM systems, insulin pumps, and digital health tools. These innovations make it easier for individuals to monitor and control their condition outside of clinical environments, offering greater flexibility and convenience. Home healthcare solutions reduce the need for frequent hospital visits or intensive care, making them more cost-effective for both patients and healthcare systems, particularly as global healthcare costs rise.

The growing demand for personalized care further supports the shift to home healthcare, enabling continuous, remote monitoring of diabetes, which improves patient outcomes and minimizes the risk of complications. The rise of telemedicine and remote monitoring technologies further bolsters this segment. Many patients prefer home management over clinical settings due to increased comfort and autonomy, particularly for chronic conditions like diabetes that require consistent care. As a result, the home healthcare segment is poised to be a key driver of growth in the next-generation diabetes therapy and drug delivery market.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Next Generation Diabetes Therapy and Drug Delivery Market in 2024. The prevalence of diabetes, particularly type 2 diabetes, is notably high in North America, driven by factors such as an aging population, changing lifestyles, and rising obesity rates. According to the CDC, over 38 million Americans have diabetes, with 90% to 95% of them affected by type 2 diabetes. While type 2 diabetes primarily affects individuals aged 45 and older, it is increasingly being diagnosed in children, teens, and young adults. This growing burden of diabetes creates a strong demand for advanced management solutions.

North America also benefits from highly developed healthcare systems, with state-of-the-art facilities and broad access to cutting-edge medical technologies, enabling the rapid adoption of next-generation diabetes therapies and drug delivery systems. As healthcare spending continues to rise, there is increasing investment in innovative diabetes management tools, improving patient access. Furthermore, private insurance coverage often plays a key role in facilitating the widespread use of these advanced technologies. The presence of industry leaders like Eli Lilly, Novo Nordisk, and Johnson & Johnson in the U.S.

further strengthens the region’s dominance, ensuring a continuous pipeline of innovation and investment in diabetes care. North America’s robust pharmaceutical industry, research institutions, and universities also contribute significantly to the development of new diabetes therapies, fostering an environment that accelerates innovation and market growth. These factors combined ensure North America’s leadership in the global next-generation diabetes therapy and drug delivery market.

Key Market Players

• Abbott Laboratories
• Dexcom Inc.
• Eli Lilly and Company
• Enteris BioPharma Inc. (Swk Holdings Corporation)
• GlySens Incorporated
• MannKind Corporation
• Medtronic plc
• Sanofi S.A.
• Senseonics, Holdings

Report Scope:

In this report, the Global Next Generation Diabetes Therapy and Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Diabetes Therapy and Drug Delivery Market, By Product Type:

• Inhalable Insulin
• Oral Insulin
• Insulin Patches
• CGM Systems
• Artificial Pancreas

Next Generation Diabetes Therapy and Drug Delivery Market, By Indication:

• Type 1 diabetes
• Type 2 diabetes

Next Generation Diabetes Therapy and Drug Delivery Market, By End user:

• Diagnostic/Clinics
• Intensive Care Units (ICUs)
• Home Healthcare

Next Generation Diabetes Therapy and Drug Delivery Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Next Generation Diabetes Therapy and Drug Delivery Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.